|
KMID : 0378019890320070125
|
|
New Medical Journal
1989 Volume.32 No. 7 p.125 ~ p.131
|
|
|
Clinical Trial of Troxipide in Peptic Ulcer
|
|
|
|
|
Abstract
|
|
|
he balance of mucosal defence factors and aggressive factors is important for ulcerogenesis. I have treated 30 cases of endoscopically diagnosed peptic ulcers (15 cases were gastric ulcer, 15 cases duodenal ulcer) with Troxipide for evaluation of the therapeutic efficacy and safety. Every patient was treated with Troxipide 100mg t.i.d. for 8 weeks or 12 weeks and underwent endoscopic, clinical, and laboratory assessments before and after treatment.
The results were as follows
1. The rate of complete endoscopic healing of gastric ulcer was 46.7% at 4 weeks, 66.7% at 8 weeks, and 80% at 12 weeks and 53.3% of duodenal ulcer at 4 weeks and 73 3% at 8 weeks.
2. Improved rate of peptic ulcer was 66.6% in excellent, fair 20%, and overall 86.6% response rate in gastric ulcer, in duodenal ulcer 73.3%, 20%, and 93.3%, respectively.
3. Manifestations of peptic ulcer had been improved above 90% after 3 weeks medication with Troxipide.
4. No patient developed any side effects of drug including blood count, renal and liver functions. This study demonstrated that Troxipide 100mg PO t.i.d. could be effective and safe in treatment of peptic ulcer disease.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|